PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.

Entrectinib(恩曲替尼) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM.  

Larotrectinib sulfate is an oral potent and selective ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).

Larotrectinib (拉罗替尼) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

Bosutinib(博舒替尼) is a novel, dual Src/Abl inhibitor.

Foretinib is an orally bioavailable small molecule with potential antineoplastic activity.

Vandetanib(凡德他尼) is a Kinase Inhibitor.

Nintedanib(尼达尼布) is an orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities.